SWOG 1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

December 10, 2018
https://clinicaltrials.gov/ct2/show/NCT03033576
Cancer - Melanoma
Principal Investigator: Ding Wang, MD
CANCER, MELANOMA, ADVANCED, REFRACTORY
Accepting Participants